ArticleFrontiers in oncology2021

Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.

Yong-Feng Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.